Showing: 1 - 5 of 5 RESULTS

Regenerative Medicine Market | Increasing Prevalence of Chronic Diseases to Boost the Market Growth

The global regenerative medicine market size is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201009005293/en/

Technavio has announced its latest market research report titled Global Regenerative Medicine Market 2020-2024 (Graphic: Business Wire)

The increasing prevalence of various chronic diseases is one of the primary factors which will drive regenerative medicine market growth during the forecast period. The incidence of many musculoskeletal disorders and bone injuries such as arthritis, osteoporosis, and severe limb trauma injuries requiring hospitalization is also increasing. Regenerative medicine opens the possibility of overcoming previously untreatable diseases using new treatment methods like processed cells for reconstructing tissues. It has the unique capability of altering the fundamental mechanisms of disease and also helps in reducing healthcare costs by eliminating the need for long-term hospitalization or drug regimes. This is leading to the increased adoption of regenerative medicine for the treatment of chronic diseases.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major regenerative medicine market growth came from the cell and tissue-based segment. Cell therapy is used to administer living cells into an individual’s body to restore the functioning of the diseased or damaged body organ. This therapy uses somatic cells and stem cells, such as embryonic stem cells, progenitor cells, hematopoietic stem cells, and mesenchymal stem cells.

  • North America had the largest regenerative medicine market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The increasing prevalence of chronic and acute diseases, the rapidly rising aging population, and high awareness about regenerative therapies will significantly influence regenerative medicine market growth in this region.

  • The global regenerative medicine market is fragmented. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. To help clients improve their market position, this regenerative medicine market forecast report provides a detailed analysis of the market leaders.

  • As the business impact of COVID-19 spreads, the global regenerative medicine market 2020-2024 is expected to have Neutral and At par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Increasing Number of Clinical Trials

Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will be presenting at the Alliance for Regenerative Medicine’s (ARM) virtual Cell and Gene Meeting on the Mesa, taking place October 12-16, 2020. Michael Redman, Executive Vice President and Chief Operating Officer of Genprex, will lead the company’s presentation.

The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day. The Cell and Gene Meeting on the Mesa is the sector’s foremost annual conference, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.

For more information on the conference, or to register, please visit https://www.meetingonthemesa.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute

Regenerative Medicine Market Share, Trend, Opportunity, Affect On Demand By COVID-19 Pandemic And Forecast 2020-2025

The MarketWatch News Department was not involved in the creation of this content.

Sep 21, 2020 (AmericaNewsHour) —
Regenerative Medicine Market Analysis
According to Verified Market Research, the Global Regenerative Medicine Market was valued at USD 19.10 Billion in 2018 and is expected to witness a growth of 22.72% from 2019-2026 and reach USD 98.10 Billion by 2026.

What is Regenerative Medicine Market?
The field of regenerative medicine comprises of abundant strategies, which mainly includes use of materials and de novo generated cells, as well as various amalgamations thereof, to substitute the lost tissue, efficiently replacing it both anatomically and functionally, or to contribute to tissue restoration. The main objective of regenerative medicine is to propagate replacement tissue or organs for patients who have sustained an injury or have had a disease that permanently damaged their tissue. National Institutes of Health defines regenerative medicine as a process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects.
Regenerative Medicine can be perceived as an interdisciplinary field of research and clinical applications which mainly focuses on the repair, replacement or regeneration of cells, tissues or organs. Regenerative Medicine mainly restores impaired function resulting from any cause. Regenerative medicine has the ability to rectify or substitute tissues and organs impaired by age, disease, or trauma, as well as to normalize congenital defects.

The Final Report will cover the impact analysis of COVID-19 on this industry:

Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10085009

Regenerative Medicine Market Outlook
Over the last decade, stem cell biology has experienced a breakthrough in scientific and technological developments that will together have foremost and continuing influence on regenerative medicine. These entails capability to produce pluripotent stem cells from adult body cells and to cultivate mini-organs from these or from adult stem cells in well-defined culture conditions. Both methodologies offer ways to develop functional cells of human tissue that could be used for transplantation and tissue repair.
Government policies favoring regenerative medicine is one of the major reasons which has been driving the market growth. The European Union (EU) and Dutch government have prioritized regenerative medicine as an area of key strategic relevance. Apart from this, rapid increase in aged population has also boomed the market in North American region. The North Carolina Tissue Engineering and Regenerative Medicine Society is an organization in the U.S. working to improve and advance basic research, commercial development and education in the field of regenerative medicine. In the U.S., two major government agencies – NIH and CIRM – gather funds for academic translational stem cell research and regenerative medicine development. Increasing global healthcare expenditure is also expected to fuel the market.

Lack of awareness and ethical issues regarding the use of Embryonic Stem Cell for R&D is expected to hinder the market for regenerative medicine. The market growth rate is highly influenced by the adoption rate of cell therapy in the market, as it is an integral part of regenerative medicine.

Regenerative medicine company Aziyo Biologics sets terms for $50 million IPO

Aziyo Biologics, which makes regenerative medical products for various tissue types, announced terms for its IPO on Wednesday.

The Silver Spring, MD-based company plans to raise $50 million by offering 2.9 million shares at a price range of $16 to $18. Insiders intend to purchase $20 million worth of shares in the offering. At the midpoint of the proposed range, Aziyo Biologics would command a fully diluted market value of $177 million.

Through its proprietary tissue processing platforms, the company has developed a portfolio of advanced regenerative medical products designed to be similar to natural biological material. Its core products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. 

Aziyo Biologics was founded in 2015 and booked $42 million in revenue for the 12 months ended June 30, 2020. It plans to list on the Nasdaq under the symbol AZYO. Piper Sandler, Cowen, Cantor Fitzgerald and Truist Securities are the joint bookrunners on the deal. It is expected to price on Wednesday, October 7, 2020.

The article Regenerative medicine company Aziyo Biologics sets terms for $50 million IPO originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article

Regenerative Medicine Market Huge Growth Opportunities and Trends to 2025

The MarketWatch News Department was not involved in the creation of this content.

Sep 29, 2020 (Market Insight Reports) —
The Regenerative Medicine Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2026. The Regenerative Medicine market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. This Regenerative Medicine Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

Top Companies in the Global Regenerative Medicine Market
DePuy Synthes, Osiris Therapeutics, Medtronic plc (NYSE: MDT), Stryker Corporation (NYSE: SYK), Acelity, Zimmer Biomet Holdings, Inc. (NYSE: ZBH), UniQure, MiMedx Group, Cellular Dynamics International, Organogenesis, Vericel Corporation, Mesoblast, Guanhao Biotech, Vcanbio, Cytori, Golden Meditech, Bellicum Pharmaceuticals, Celgene, Gamida Cell, Stemcell Technologies, among others.

According to this study, over the next five years, the Regenerative Medicine market will register a 24.3% CAGR in terms of revenue, the global market size will reach $ 19360 million by 2025, from $ 8118.3 million in 2019.

Market Overview:
Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the “process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function”. It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body’s innate healing ability to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds, and ocular diseases.

Get a Sample PDF Copy of the Latest Research on Regenerative Medicine Market 2020 Before the purchase
https://www.marketinsightsreports.com/reports/01301807201/global-regenerative-medicine-market-growth-status-and-outlook-2020-2025/inquiry?Mode=46&Source=MW

According to the estimation of the World Health Organization, there is an increasing prevalence of diabetes among adults over the age of 18 years, which has increased to 8.5% in 2014 compared to 4.5% in 1980 across the globe. As per the estimation of the Arthritis Foundation, the number of people expected to be diagnosed from arthritis will be more than 78 million, by 2040.

The 21st Century Cures Act, approved in December 2016, created room for the establishment of the Regenerative Medicine Innovation Project (RMIP). NIH (National Institute of Health) is leading the RMIP in coordination with the FDA. The 21st Century Cures Act approved $30 million in federal awards over four years (2020-2020) for the RMIP, thus accelerating the arena by aiding clinical research on mature stem cells while endorsing the uppermost morals for scientific research and patient safety.

Market Insights:
Currently, some companies in the world can provide regenerative medicine services, mainly concentrating in the USA. The main market